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Background/aim: Rheumatoid pulmonary nodule can be detected in up to 32% of rheumatoid arthritis (RA) patients and approximately
one-third of nodules may cavitate. We aimed to evaluate characteristics of patients with RA developing cavitary pulmonary nodular
(CPN) lesions under disease-modifying antirheumatic drugs (DMARDs), follow-up of both cavitary and solid nodules, and their
outcome with the treatment.
Materials and methods: RA patients who presented with CPN lesions during follow-up were recruited retrospectively in this case
series analysis. Total numbers and mean diameters of cavitary and solid nodules in each thorax computed tomography (CT) have been
determined and followed up by two experienced pulmonary physicians. Moreover, changes in treatment after the development of the
CPN lesions and characteristics of cavitary nodules were collected.
Results: Eleven patients with CPN lesions were reported. At the time of CPN diagnosis, more patients were taking leflunomide than
methotrexate (81% vs 19%). Half of the patients were receiving biologic therapy and only 18% were taking anti-TNF drugs. After a
median of 24 (3–65) months of follow-up, the regression of CPN lesions was determined in 45% (5/11) of patients. Four of these 5 (80%)
patients were switched to a treatment regimen without leflunomide and three of them to nonanti-TNF biologic treatment or targeted
synthetic DMARDs (tocilizumab, tofacitinib, and rituximab).
Conclusion: CPN lesions seen in RA patients are often pulmonary manifestations of the underlying disease; however, one must rule out
malignancies or infections. If lesions progress under DMARDs, it is advised to discontinue synthetic DMARDs (LEF/MTX) and switch
to another biological DMARD with different modes of action
Key words: Biologic drugs, cavitary nodule, leflunomide, rheumatoid arthritis, solid nodule

1. Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease
typically involving small joints. Pulmonary involvement
is the most common extraarticular manifestation of the
disease. Pulmonary disease, which is a major source of
morbidity and mortality in RA, manifests most commonly as
interstitial lung disease (ILD), airways disease, rheumatoid
nodules (RN), and pleural effusions [1].
The prevalence of rheumatoid pulmonary nodules,
also called necrobiotic nodules, ranges from less than 0.4%
in radiological studies to 32% in lung biopsies of patients
with RA [2]. These nodules can sometimes cavitate.
Nodules usually present a diagnostic challenge rather
than therapeutic. Nodules in RA patients should be

evaluated similarly to those in any other patient presenting
with solitary or multiple pulmonary nodules, as nodules
may reflect the presence of infection, malignancy, or other
inflammatory diseases. Biologic drugs are now widely
used for treating RA. Various side effects, mainly infection,
have been described with these drugs. The efficacy of
these agents for the treatment of pulmonary involvement
of disease has not been specifically evaluated in large
placebo-controlled randomized trials.
We report characteristics of 11 patients with RA
developing cavitary pulmonary nodular (CPN) lesions
under disease-modifying antirheumatic drugs (DMARDs)
and follow-up of cavitary nodules and their outcome with
the treatment were reported.
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2. Materials and methods
RA patients who presented with CPN lesions during
follow-up between September 2009 and April 2019
in rheumatology outpatient clinic were recruited
retrospectively in this case series analysis. Diagnosis of the
CPN lesions was made with computed tomography (CT)
scan and indication for imaging of these patients were
constitutional/respiratory symptoms or any abnormality at
routine annual conventional radiography during biological
treatment. Characteristics of the patients, positron
emission tomography (PET), and biopsy (if available)
findings were collected from patient reports. Patients
without biopsy were the ones who did not accept biopsy or
who had contraindication for biopsy (with cardiac failure
and arrhythmia treated by the cardiac pacemaker). In
addition to these, changes in treatment after development
of the CPN lesion and characteristic of cavitary nodules
were collected. Outcome assessment focused mainly
on the number and characteristics of all nodules (solid,
cavitated) with the modification of treatments, but we
also evaluated cavitary nodules separately. Total numbers
and mean diameters of cavitary and solid nodules in
each CT have been determined with the agreed decision
of two experienced pulmonary physicians, who were
aware of the clinical data of the patients. An increase in
total nodule count or new cavitation of a solid nodule at
CT was accepted as a progression of the lesion. It is also
accepted as a progression of the lesion if there is a 20%
or more increase of mean nodule size even though total
and cavitary nodule count is stable. A decrease in total
or cavitary nodule count and a 30% or more decrease in
mean nodule size is accepted as regression of the lesion.
The study was approved by the local clinical research ethics
committee (reference number: 09.2019.592)
3. Results
3.1. Patient demographics
Table 1 summarizes demographic and clinical
characteristics of patients. Eleven patients (5 males and 6
females) were reported with a median age of 51 (30-61)
years at diagnosis and median disease duration of 17.5
(8–30) years. Eight patients had a history of smoking,
four patients had subcutaneous rheumatoid nodules,
and five had erosive deforming joint involvement. Nine
patients (81%) were under the treatment of a median of
82 (10–100) months with leflunomide (LEF) and 2 (19%)
patients had 90 (80–100) months methotrexate (MTX)
usage when CPN lesion was detected. Seven out of nine
patients with LEF treatment had a history of methotrexate
(MTX) treatment; two patients had a history of rapid skin
nodulosis with MTX. Cumulative MTX dosage was less
than 1 g for 3 patients. Concomitant with conventional
disease-modifying antirheumatic drugs (csDMARDs), 6
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(54%) patients received biologic treatment. One patient
was receiving rituximab (median duration: 12 months), 3
patients were receiving abatacept (median duration:10 (718) months), and 2 patients were receiving tumor necrosis
factor (TNF α) inhibitors (infliximab, etanercept) (median
duration: 69.5 (48–91) months).
Before initiation of biologic drugs (except rituximab),
each patient was screened for tuberculosis and underwent
conventional radiography, clinical pulmonary examination,
and ppd/QuantiFERON test, and tuberculosis prophylaxis
(9 months of isoniazid) was given to 5 of them as the
results of these tests.
Two patients received antituberculosis treatment after the
detection of CPN; the negative QuantiFERON test turned
positive during abatacept treatment in 1 patient (case
4) and biopsy of the nodule was necrotizing granuloma
for the other one although tuberculosis bacilli were not
detected (case 8). After antituberculosis treatment, there
was no regression at the cavitary nodules.
3.2. Clinical symptoms and laboratory findings
Respiratory symptoms were reported by 2 patients and
constitutional symptoms by 2 patients while the others were
asymptomatic during the diagnosis of CPN. All patients
were seropositive, 2 patients had p ANCA (antinuclear
cytoplasmic antibody)-positive, but the ELISA test for
anti-MPO (myeloperoxidase) and PR3 (proteinase) were
negative. Extensive examinations for microbial organisms
(mycobacteria and opportunistic infections) were all
negative (including cultures from bronchoscopy and
bronchoalveolar lavage).
3.3. Imaging findings
A total of 48 CTs were evaluated by two experienced
pulmonary physicians. We are presenting CT findings
showing cavitary and solid nodules of our patients in Figure.
The median numbers of total cavitary and solid nodular
lesions were 8 (3–41) and 12 (1–61) at the beginning and
after follow-up, respectively. Moreover, numbers of cavitary
lesions were 1 (1–4) and 2 (0–7) at the beginning and after
24 (3–65) months of follow-up, respectively.
Fluorodeoxyglucose (FDG) PET/CT scan examination
of nodules was performed to exclude malign conditions
in 7 patients. We determined that both mediastinal
lymphadenopathy (LAP) and cavitary-solitary nodules
had increased uptake with a standardized uptake value
(SUV) of 1.6–7.9 FDG. Salivary gland adenocarcinoma
was detected in one of the patients with 12 FDG uptake
value at the submandibular area, but biopsy from
mediastinal lymph node (11 FDG) showed tuberculosisnegative necrotizing granuloma.
3.4. Patient outcomes
We evaluated CTs of patients for the total (solid/cavitary)
nodules at the end of 28 (3–65) months follow-up and 4
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Figure. Solid and cavitary nodule of our patients.

(36.3%) patients were diagnosed with regressed lesions
while 7 (63.7%%) patients had progressive lesions
compared to previous CTs (as shown in Table 2). At the
time of CPN diagnosis, more patients were taking LEF
than MTX as csDMARD (81% vs 19%). Half of the patients
were receiving biologic therapy and only 18% (2/11) were
receiving anti-TNF drugs. After a median of 24 (3–65)
months of follow-up, the regression of CPN lesions was
determined in 45% (5/11) of the patients. Four out of
these 5 (80%) patients were receiving a treatment regimen
without LEF when their last CT was performed. Three
of them were taking nonanti-TNF biologic treatment or
targeted synthetic DMARDs (tocilizumab, tofacitinib, and
rituximab), and one of them was receiving azathioprine
(as shown in Table 2).
4. Discussion
We are presenting the largest case series so far in the
literature with 11 seropositive RA patients with long
disease duration who were diagnosed with CPN in their
follow-up. Moreover, our study has an advantage of
presenting the long-term follow-up of cavitary lesions
in RA patients, whereas the literature generally focuses
on short-term consequences of treatments. Our patient
profile is compatible with the literature where rheumatoid
nodules/cavitary lesions are more common in patients

with smoking, long disease duration, and seropositivity.
[3] After the exclusion of malignancy, vasculitis, and
infection, rheumatoid nodules had been followed with CT,
but treatment was mainly based on joint activity. Patients
with CPN diagnosis were mostly taking leflunomide and
biologic treatment. At 2 years follow-up time, 45% of CPN
cases recovered. Almost all the improved cases were not
using synthetic DMARDs (LEF/MTX) and taking nonTNF biologic treatment or targeted synthetic DMARDs
(tocilizumab, tofacitinib, and rituximab).
The rheumatoid nodule is one of the characteristic
lesions of RA and is regarded as a systemic feature of the
disease. Histologically, it is a granuloma and activated
macrophages are prominent within the rheumatoid
nodule. These macrophages in the lesion are the likely
source of the proinflammatory cytokines interleukin1beta and tumor necrosis factor-alpha [4]. This would be
consistent with evidence that immunologically mediated
granulomas in other diseases. These granulomas are
dynamic structures that rely on persisting effective T-cell
immunity and recruitment of monocyte/macrophages to
maintain the granuloma [5]. Rheumatoid nodules may
cavitate in approximately one-third of cases, presumably
due to ongoing vasculitis with ischemic necrosis [6]. We
know that drugs used to treat the joint activity of RA can
result in lung disease [7]. Progression and acceleration of
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Table 2. Characteristics of Nodules, Disease Activity, and Prognosis with Different Treatment Agents

Case1

Case2

Case3

Case 4

Case 5

Case 6

Case 7

Case 8
Case 9

Case 10

Case 11

CT

Number
of total
nodules

Number
Mean size
of cavitary of nodules
nodules
(mm)

CRP/
Sedimentation
(mm/hour)

DAS28/ Outcome of
CRP
nodule

Treatment during the CT
scan

baseline

3

2

10.66

5/29

NA

ABT, LEF

6 months

4

2

7.75

3/18

NA

Progression

steroid, CERT, LEF

24 months

5

5

11

9.6/NA

NA

Progression
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30 months

7

3

11.85

7/37

NA

Progression

No treatment

34 months

7

6

9.85
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NA

Progression

LEF

45 months

3

0

6.33

5.5/NA

3.84

Regression

Tocilizumab

baseline

8

1

4.5

3/7

0.96

3 months

8

0

4.5

0.7/9

0.96
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5

4

18.4

17/60

2.59

3 months

5

3
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64/71

4.17

Regression

LEF

18 months

1

0

6

4.8/NA

1.6
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Tofacitinib

baseline

12

1

4.75

20/38

NA

10 months

12

2

5.25

16/31

2.11

baseline

5

4

17.4

22/52

NA

5 months

5

5

19.6

92/94

NA

Progression

LEF; ABT

9 months

10

5

15.2

158/86

NA

Progression

LEF; ABT

21 months

15

6

14.4

63/68

2.97

Progression

LEF; ABT

28 months

15

7

14.2

86/71

NA

Progression

LEF, ABT

baseline

10

1

3.2

3.2/37

1.5

11 months

14

1

4.92

27/89

3.97

Progression

LEF (11th month)

19 months

32

2

7.4

18/43

2.08

Progression

LEF, ABT (3rd months)

33 months

29

5

6.27

11/24

2

Progression

LEF

baseline

13

1

4.31

NA/NA

NA

17 months

14

2

5.28

79/31

NA

Progression

ABT, LEF

24 months

15

3

5.23

6/38

2.15

Progression

LEF

baseline

43

1

4.91

6.7/60

NA

12 months

61

4

7.18

4/70

NA

baseline

5

2

10

4/51

1.54

12 months

5

3

10.6

5/24

1.61

baseline

3

1

2.66

5.7/28

1.65

11 months

3

0

2.66

NA

NA

Regression

AZA

21 months

3

0

2.66

2.9/33

1.41

Stable

AZA

36 months

4

0

2.75

NA

NA

Progression

AZA

51 months

4

0

2.75

14/66

1.96

Stable
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65 months

4

0

2.75

0.16/32

0.96

Stable
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Baseline

14

1

8.14

14/42

1.93

3 months

14

2
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2

7.76
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3
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Progression
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LEF
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LEF
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LEF; LDS
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LEF,SZP
LEF

MTX, LDS

AZA: Azathioprine, ETN: Etanercept, LDS: Low Dose Steroid, LEF: Leflunomide, MTX: Methotrexate, ABT: Abatacept, CERT: Certolizumab, CT:
Computed Tomography, IFX: Infliximab, RTX: Rituximab
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rheumatoid nodule formation are well-known following
MTX and LEF therapy in RA patients. The most accepted
mechanism of MTX in RA patients is on the adenosine
pathway promotion, which increases the activation
of all types of adenosine receptors. Adenosine has a
beneficial effect on reducing inflammation by the A2A
receptor and by the A1 receptor it caused the promotion
of multinucleated giant cell formation by human
monocytes, which was suggested to be the cause of MTX
induced nodulosis in RA patients [8]. LEF suppress the
inflammation in synovium of RA patients by inhibiting
the mitochondrial enzyme dihydroorotate dehydrogenase
of activated T-cells [9]. However, the exact mechanism,
by which LEF causes pulmonary nodules/CPN is unclear.
Most of our patients were under LEF treatment during
the detection of CPN. Like our results, previous case
reports published in the literature detected CPN during
LEF treatment [6, 10-12]. Among our patients, 3 out of
9 discontinued LEF and recovered after they received
tocilizumab, tofacitinib, and azathioprine treatment. Two
of 6 patients who continued to take leflunomide recovered,
but the rest 4 were progressed. Two of the progressed cases
on leflunomide received abatacept as a biologic treatment.
Reducing T-cell immunity or its interaction with other
critical factors such as TNF α may cause loss of structure
in the rheumatoid nodule [13]. Perhaps, we may think
that induction of immunosuppressive drugs that affect
T-cell inhibition, such as abatacept and LEF, may lead to
disruption of granuloma results in a cavitation of nodules.
The positive effects of rituximab treatment on
pulmonary rheumatoid nodules were reported by Glace
et al. [14]. One of our patients with CPN lesions received
rituximab and all cavitary nodules disappeared at 6
months. Here, rituximab was administered to all patients,
and nodules disappeared in eight patients, or the sizes
were reduced significantly. MTX or LEF therapy was
not discontinued after starting rituximab treatment. In
contrast with the study by Grace et al., 80% of our patients
with regressed CPN lesions were not receiving LEF or
MTX at their last visit.
Reports show that the effect of TNF α on inflammatory
mechanisms in rheumatoid nodules is less effective
compared to joints, so treatment with TNF α inhibitors
cannot treat pulmonary nodules [15]. In our study, 2
patients were diagnosed with CPN during anti-TNF
therapy although their joint activities were under control.
After discontinuation of these drugs, the number of
cavitary nodules decreased, but the number of solid ones
increased. A patient with CPN switched to certolizumab
pegol therapy after abatacept treatment, and though joint
activity improved, new cavitary nodules progressed.
It is still controversial whether this is a result of the
ineffectiveness of anti-TNF therapy on nodules or disease/
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nodule natural progression [5]. Toussirot et al. reported a
case series for 11 RA patients who had pulmonary solid and
cavitary nodules under the treatment of anti-TNF. After
they discontinued the anti-TNF therapy, stability or even
resolution of the nodular lesions had been determined,
but 2 of these 3 patients with complete resolution received
rituximab treatment. They have seen the development of
nodular lung lesions in a patient with the reintroduction of
anti-TNF therapy. [13] Although Toussirot et al. described
that none of the solitary nodules progressed even though
anti-TNF therapy was continued in 4 patients, we
determined an increase in size and number of cavitary
and solid nodules in a patient followed for 2 years under
the treatment of anti-TNF therapy and leflunomide. Derot
et al. [16] reported definitive regression of rheumatoid
nodules after the suspension of etanercept therapy. Glace
et al. [14] reported ten cases with pulmonary rheumatoid
nodules that developed during the administration of
traditional DMARDs and/or anti-TNF therapy.
There is a case report by Andres et al. [17] where
pulmonary nodules were successfully treated by
tocilizumab. With a CPN lesion, one of our patients showed
regression in these lesions with tocilizumab treatment.
Some case reports have suggested a response to high-dose
steroids for pulmonary nodules [18]. Among our patients
none of the patients with the outcome of stable/regressed
lesions received high-dose steroids.
There are case series of RA patients presenting with
rheumatoid nodules in the literature, but data on CPN
lesions is very limited. Alpay-Kanıtez et al. presented
two RA patients with CPN and a literature review of 11
cases. At the time of CPN detection, 8 and 4 patients were
under LEF and MTX treatment respectively [10]. In line
with these 11 cases, most of our patients with CPN lesions
were using leflunomide. With the discontinuation of LEF/
MTX, regression of CPN lesions was observed in most of
the 11 cases in this literature review. Similarly, almost all
the patients in our case series were not using synthetic
DMARDs (LEF/MTX). In contrast to these previous cases
with CPN lesions, none of our patients were treated with
corticosteroids and/or cyclophosphamide treatment. In
addition, we determined recovery of the lesions in our
patients who were taking non-TNF biologic treatment or
targeted synthetic DMARDs (tocilizumab, tofacitinib, and
rituximab).
Eight patients underwent PET/CT scan to rule out
malignancy and nodules showed mild-moderate FDG
uptake. There are reports in the literature that determine
a modest increase in FDG uptake of RA nodules and
our results support them [19]. Therefore, PET/CT
cannot distinguish inflammation from malignancy.
However, 1 patient was diagnosed with submandibular
adenocarcinoma under PET/CT guidance but biopsy from
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mediastinal lymph node (11 FDG) showed tuberculosis
negative necrotizing granuloma. Therefore, the PET/CT
scan can be useful to choose which nodule is more efficient
for biopsy or to find out if there is another organ pathology.
Our study has some limitations. We did not have
the disease activity of all the patients during the CT
scan because of the retrospective design of the study. In
a previous study, no relationship was reported between
nodules and disease activity [11]. We also presented the
initial CT scans and treatments of patients with cavirtary
lesions, but we do not know exactly when the cavitary
lesions occurred. The evaluators of the CT findings were
not blinded to clinical data and interclass correlation
was not calculated for them. However, they reached total
agreement for the progression and regression of the disease.
We did not have histopathology from all nodules, but we
followed up the patients for a median of 24 (3–65) months
and none of the lesions progressed to other diagnoses.
Additionally, core needle biopsies should be interpreted
carefully because the histology of the rheumatoid nodule

has marked overlap with granulomatous infection and
Wegener granulomatosis [20].
In conclusion, CPN seen in RA patients are often
pulmonary manifestations of the underlying disease;
however, one must not rule out malignancies or infections.
If these lesions develop under DMARDs especially with
LEF and biologic treatments with anti-TNF therapy, it is
advised to discontinue synthetic DMARDs (LEF/MTX)
and switch to biological DMARDs with different modes
of action. In addition, improvement of the CPN lesions
might be seen with non-TNF biologic treatment or
targeted synthetic DMARDs (tocilizumab, tofacitinib, and
rituximab).
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